Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70039 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Yong-Wei Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei City, Taiwan. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipidemias. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Higher serum cholesterol levels have been associated with an increased risk of dry eye disease (DED). The relationship between statin (HMG‐CoA reductase inhibitor) use and DED in patients with hyperlipidemia remains unclear. To investigate the association between statin use and the risk of DED in patients with hyperlipidemia, we conducted a population‐based retrospective cohort study utilizing data from Taiwan's Longitudinal Generation Tracking Database. Patients were categorized into statin users and nonusers, with a 5‐year follow‐up period. The study identified patients with newly diagnosed hyperlipidemia, excluding those with prior DED diagnoses. Matching and adjustments for covariates resulted in 41,931 individuals in each group. Patients receiving statin therapy were compared with those unexposed. Cumulative exposure doses were also evaluated to assess dose–response relationships. The primary outcome was the incidence of DED diagnosed during the follow‐up period. Cox proportional hazards regression models estimated the risk of DED, and conditional logistic regression analyzed the dose–response effect of statin exposure. Among 41,931 matched pairs, statin users exhibited a slightly increased risk of developing DED compared with nonusers (adjusted hazard ratio, 1.06; 95% CI, 1.02–1.11; p < 0.01). However, no dose–response relationship was observed between statin exposure and DED risk. Statin use among patients with hyperlipidemia is associated with a marginally higher risk of DED. These findings underscore the importance of regular eye examinations in this patient population to facilitate early detection and management of DED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei City, Taiwan.
- Department of Pharmacy, National Taiwan University Cancer Center, Taipei City, Taiwan.
- Department of Pharmacy, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, Taiwan.
- Department of Ophthalmology, Taipei Medical University Hospital, Taipei City, Taiwan.
- Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan.
- Department of Psychiatry, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA.
ORCID-Profile: Sian-De Liu, Guan-Ling Lin, Evelyn-Jou-Chen Huang, Li-Hsuan Wang
Zitieren
APA
Wang, Y. W., Liu, S. D., Lin, G. L., Huang, E. J., Keller, J. J., & Wang, L. H. (2024). Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study. Clinical and Translational Science. https://doi.org/10.1111/cts.70039
Vancouver
Wang YW, Liu SD, Lin GL, Huang EJ, Keller JJ, Wang LH. Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study. Clinical and Translational Science. 2024. doi:10.1111/cts.70039
BibTeX
@article{Wang2024,
author = {Wang, Yong-Wei and Liu, Sian-De and Lin, Guan-Ling and Huang, Evelyn-Jou-Chen and Keller, Joseph Jordan and Wang, Li-Hsuan},
title = {Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70039}
}
EUVIMED